Dr Luis Paz-Ares speaks to ecancer about the primary results of the phase 3 IMforte trial.

This trial assessed the effectiveness of lurbinectedin combined with atezolizumab for treating extensive stage small cell lung cancer.

Dr Paz-Ares highlights the results of the study saying that significant improvements in progression-free survival were seen, increasing from 2.1 months to 5.4 months, and overall survival, rising from 10.6 months to 13.2 months.

The treatment's safety profile remained predictable, indicating its potential as a new standard of care for patients in need of third line maintenance therapy.